Gene Hackman death: Alzheimer's impact on actor in days after wife's death
Gene Hackman may not have realized his wife, Betsy Arakawa Hackman, was dead during his final weeks due to his advanced Alzheimer's, according to forensic pathologist Dr. Michael Baden. The legendary actor died due to hypertensive atherosclerosis cardiovascular disease, with Alzheimer's disease as a significant contributing factor, New Mexico officials confirmed Friday.
Hackman likely survived alone in the home for about a week, until he died around Feb. 18, which was the last time activity was recorded on his pacemaker.
"I think what [happened] here is he didn't realize it and … didn't understand that she was dead. He didn't understand that he needed to call 911," Dr. Baden told Fox News Digital.
"It sounds like he's kind of wandered around, was able to drink water from … [the] kitchen sink or even get some food out of the refrigerator … [he] probably couldn't cook anything but could eat bread or something if he was hungry," he explained.
Hackman's wife, a classical pianist, died due to Hantavirus Pulmonary Syndrome, which is transmitted from animals to humans and is commonly found in rodents, the New Mexico Department of Health confirmed. Her autopsy determined the manner of death as natural. Authorities believe she died on or about Feb. 11.
Leading up to their mysterious deaths, the actor's wife appeared to be the primary caretaker of Hackman, according to Dr. Baden.
"It looks like she was really taking good care of him," he noted. "She goes first and then … pointing to the evidence that was presented for about six, seven days – 11th to the 17th -- when they [knew] that something [had] happened to him."
Chief Medical Investigator Dr. Heather Jarrell performed a full autopsy on Hackman the day after his body was discovered, which showed "severe heart disease, including multiple surgical procedures involving the heart, evidence of prior heart attacks, and severe changes of the kidneys due to chronic high blood pressure."
She added, "Examination of the brain showed advanced Alzheimer's disease as well as blood vessel changes in the brain secondary to chronic high blood pressure."
Jarrell noted that Hackman's pacemaker data indicated an "abnormal rhythm of atrial fibrillation" on Feb. 18. She said it was "reasonable to conclude" Arakawa died the week before Hackman, with the actor's death likely on Feb. 18.
"Based on the circumstances, it is reasonable to conclude that [Arakawa] passed away first, with February 11th being the last time that she was known to be alive," Jarrell said.
WATCH: NEW MEXICO OFFICIALS CONFIRMED GENE HACKMAN AND HIS WIFE BETSY'S CAUSE OF DEATHS
Fox News Digital medical contributor, Dr. Marc Siegel added that if Hackman's Alzheimer's was "severe," he wouldn't have realized his wife was dead.
"If he was incapable of calling 911, and getting her seen, and just sat there for a week, then he either went into a state of great despondency or was somehow incapacitated himself," Dr. Siegel remarked. "Or his Alzheimer's was so severe that he was incapable of even noticing what was going on."
Meanwhile, when asked if authorities believed Hackman was able to live on his own and survive after his wife died, Chief Medical Investigator Dr. Jarrell noted that the Oscar-winning actor was in "a very poor state of health."
"Mr. Hackman showed evidence of advanced Alzheimer's disease," Jarrell said. "I'm not aware of what his normal daily functioning capability was. He was in a very poor state of health, and he had significant heart disease. And I think ultimately that is what resulted in his death."
Detectives initially described the couple's deaths as "suspicious enough in nature to require a thorough search and investigation," according to a search warrant affidavit obtained by Fox News Digital.
LISTEN: GENE HACKMAN 911 CALL
Officials confirmed that no external trauma was seen on either Hackman or Arakawa, and New Mexico authorities promptly launched a criminal investigation into their deaths.
Hackman and Arakawa previously tested negative for carbon monoxide, Sheriff Adan Mendoza confirmed last week. Their residence was tested for the colorless, odorless gas and was cleared by the Santa Fe City Fire Department after authorities were unable to find evidence of a carbon monoxide leak or poisoning.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
9 minutes ago
- Time Magazine
Big Data Can Make America Healthier. Here's How to Do It Right
Big data can help make Americans healthier, and the Trump Administration has stated—in its recently released Make America Healthy Again report and elsewhere—that building a national big-data platform is one of its primary goals. As scientists who use large data sets to study health, we're excited about its potential and the willingness of the federal government to invest in it, particularly since big data has been underutilized in the U.S. compared with other developed countries—and since the number of ways it can be used grows nearly daily. It's a huge opportunity. But there are lots of concerns when assembling sensitive health data and combining it with other sensitive data, like credit scores, tax records, employment, educational records, and more. Some of those concerns with the Administration's plans have already surfaced. The Administration's first goal of assembling big data to studying autism has left some worried that if used inappropriately, such data could lead to harm, rather than help, for those with autism. Others worry that big data could be used to perform and justify shoddy research that supports predetermined conclusions without adhering to rigorous scientific methods—a concern reinforced by the discovery that the Make America Healthy Again report cited non-existent sources to support its claims. So how can we reap the benefits of big data while minimizing its risks? Here are some guiding principles: 1. Link the highly siloed health care and government data we already have The health care system already possesses health data on millions of Americans. Medical records are now almost always digitized, permitting doctors' notes, medical imaging, laboratory tests, insurance claims, and more to be linked (in theory) across doctors' offices, hospitals, nursing homes, and any other place people receive care. However, data collected about a patient in one setting often doesn't get connected to data from other settings—making it hard for researchers to get a full picture of what, exactly, is happening to each of us within the larger health care system. The federal government also has data on us that can be connected to health care data to answer important questions. For example, comprehensive and detailed data on Americans' occupations linked with health, insurance, and other data could help shed more light on relationships between our work and our health—helping to better answer curious questions like why taxi drivers are less likely to die from Alzheimer's disease or why female physicians don't outlive their male colleagues. The first step of making big data more helpful is to simply link the data—which, while possible, is difficult to accomplish without centralized effort. Once linkages have been made, data can be anonymized so that those studying sensitive questions aren't privy to confidential information about specific individuals. 2. Create capacity for researchers to securely link to other valuable data In addition to governmental data, many other sources of data can provide insights into our health. For example, smartwatches not only have data on how our hearts are beating (e.g., they can identify abnormal heart rhythms like atrial fibrillation), but they can also identify subtle changes in mobility that might be predictive of early neuromuscular diseases like Parkinson's disease. Meanwhile, grocery stores have data on the foods we eat, and with increasing interest in how diet affects our lives, these data could be linked to detailed measures of health. Similarly, social-media platforms possess data that can offer insights into changes in our mental health, and through large-scale analysis of online photos could even identify, in real time, early visible markers of disease. These are moonshots, of course, and whether we want to use data in this way is an open question. But the potential to improve health could be large. Creating a way for scientists to link outside data to existing government and health data—while responsibly maintaining individual anonymity after the linkage—could open many novel research opportunities. 3. Invest in data-research infrastructure Keeping all of these data sources organized, secure, and accessible to scientists is a tall order. Researchers who use big data often dedicate substantial resources to finding the data they need, organizing it, and ensuring its accuracy; the better the database is maintained, the easier it is for researchers to actually perform their analyses. The secure online platform where Medicare and other government health care data are currently accessed has been described by researchers as 'tedious and prone to system errors' and in need of major improvements. Meanwhile, security concerns have led the government to stop letting researchers store the data on their own secure servers, the easiest and most cost-effective way to actually work with the data. Access to Medicare data by researchers has become prohibitively expensive, costing about $30,000 a year or more for a single user to work on one project using the online platform. Proposals to drastically cut medical research funding have been reported, and if passed, these research funding cuts will come at the cost of discoveries to improve health that will never be made. High-quality research of any kind requires investment, whether it's in a biology lab under a microscope or working with data on powerful computers. A new data platform is only as valuable as researchers' ability to access it in a functional and cost-effective way. Any roadmap to designing a national data platform that links together health care and other sensitive data must consider the many valid concerns about collecting data in the U.S., including privacy concerns and how data will be used. The Pew Research Center finds that large majorities of Americans say they are concerned about how the government uses data collected about them (71%), while also admitting that they have little to no understanding of what the government even does with such data (77%). Here are some strategies—in addition to many of the cybersecurity and privacy safeguards already in place—to both protect the data and help earn the public trust: 1. Strictly limit data access to vetted researchers Mistrust and unease with government data collection is readily traceable to historical abuse of Americans' data (as well as recent allegations of improper access), so it's not surprising that many are wary of the Trump Administration's plans. Ensuring data cannot be weaponized by the government against individuals is perhaps the single biggest barrier to creating a useful database, but it can be done. Those currently using federal health care data must already undergo training and comply with very high data-security standards. Misuse of the data—such as even attempting to figure out the identity of an anonymous individual in the data—or failure to protect patient privacy can lead to criminal penalties. A platform of sensitive data without well-delineated restrictions on who can use it and what they can use it for is a recipe for problems. Other ongoing efforts by the Administration to compile data under the vague goal of 'increasing government efficiency' have been met with pushback and lawsuits from organizations concerned about data being used against members of the public. 2. Require analytical plans and ethics-board approval up front Current use of federal health data also requires researchers to provide the government detailed plans to justify the use of specific data. This allows the government to ensure that no more data than is needed to answer the specific question is provided to researchers. Researchers must also obtain ethical approval from an Institutional Review Board prior to accessing and analyzing data, a second checkpoint. These boards, which exist in light of egregious failures of medical research ethics in the 20 th century, help ensure that analyses are designed to minimize risk to patients—even if it is only their data, and not their bodies, at risk. 3. Emphasize true transparency Transparency into who is using this sensitive data and what exactly they are doing with it can engender trust between researchers and the American public. Just like researchers already do for clinical trials, those accessing the data platform should specify their plans in advance, and those plans should be easily and publicly available. Transparency around which data were accessed and what computer code was used to analyze it not only promotes trust, but such data- and code-sharing practices among researchers make it easier to appraise the quality of the work, identify mistakes, and root out misconduct. We can only assume that Americans' unease with governmental data use stems from knowledge that, as with all powerful tools, linked data has the potential to be used in potentially harmful ways. But when in the hands of qualified scientists using rigorous scientific methods and privacy safeguards, a robust real-world data platform like this could lead to new discoveries about how all of us can lead healthier lives.
Yahoo
4 hours ago
- Yahoo
Do you need a magnesium supplement? Experts share symptoms of deficiency
Magnesium is said to be a natural remedy for a variety of ailments — but is it really necessary to supplement, and if so, how much do you need? Fox News Digital spoke to multiple health experts about the multipurpose mineral, which plays a role in over 300 of the body's enzyme systems and helps with energy production, muscle and nerve function, and blood pressure regulation. Magnesium may help lower the risk of certain diseases and could help to improve sleep, reduce stress and anxiety, and prevent nighttime muscle cramps, sources said. Common Supplements And Medications Could Cause Liver Damage, Studies Show The nutrient "supports a stable heartbeat and prevents arrhythmias, works with calcium and vitamin D to keep bones strong, and aids insulin sensitivity and glucose metabolism," Dr. Heather Viola, a primary care physician with Mount Sinai Health System in New York City, told Fox News Digital. Magnesium can also help with constipation relief, migraine prevention and PMS symptoms, according to Eleana Quattrocchi, a pharmacist and associate professor of pharmacy practice at Long Island University in Brooklyn, New York. Read On The Fox News App Many Americans do not get enough magnesium in their diet, according to the National Institutes of Health (NIH) Office of Dietary Supplements. "Habitually low intakes of magnesium induce changes in biochemical pathways that can increase the risk of illness over time," the NIH website states. Studies have shown that up to 15% of people in the U.S. could experience magnesium deficiency. Common Daily Vitamin Could Slow Biological Aging, Major Study Suggests Lack of magnesium can raise the risk of hypertension, cardiovascular disease, type 2 diabetes, migraine headaches and osteoporosis. Potential symptoms include insomnia, muscle cramps, constipation, nausea and vomiting, fatigue, weakness, numbness, tingling, personality changes and heart arrhythmias, experts say. In severe cases, hypocalcemia (low calcium levels) or hypokalemia (low potassium levels) might occur, according to the NIH Office of Dietary Supplements. Blood tests can help detect low levels, but Viola cautioned that those tests "aren't perfect" because most magnesium is inside cells, not in serum. Certain medical conditions, alcoholism, some medications and a diet lacking in the mineral may contribute to magnesium deficiency. "People with gastrointestinal disease, such as Celiac disease or Crohn's disease, or those who have had a gastric bypass may develop magnesium deficiency," Sue-Ellen Anderson-Haynes, a spokesperson for the Academy of Nutrition and Dietetics and a registered dietitian who owns 360Girls&Women in Massachusetts, told Fox News Digital. The recommended daily dietary intake of magnesium is 310 to 320 mg per day for adult women and 400 to 420 mg per day for adult men. "The majority of magnesium is found in plants liked nuts, seeds and beans," Anderson-Haynes told Fox News Digital. "For reference, 1 ounce (2 tablespoons) of pumpkin seeds provides 156 mg of magnesium and 1 ounce of chia seeds is 111 mg (26% DV) of magnesium."Common Household Spice May Interfere With Medicines, Study Suggests Some specific sources of magnesium include peanut butter, bananas, avocado, nuts (almonds), black beans, leafy greens (like spinach and kale), whole grains, yogurt and dark chocolate. While dietary sources are the best way to meet daily magnesium requirements, supplements are recommended in certain cases, health experts told Fox News Digital. "A supplement should be taken when a known deficiency or a health condition is present with excessive magnesium losses, like alcoholism," Samantha Dieras, a registered dietitian and director of ambulatory nutrition services at the Mount Sinai Hospital in New York City, told Fox News Digital. Physicians may recommend supplements for magnesium-deficient patients or for individuals who are taking certain medications, such as diuretics or Proton pump inhibitors that can deplete magnesium, Viola noted. For more Health articles, visit It is possible to ingest too much supplementation. "You can get too much magnesium, but mainly from supplements, not food," Viola said. "It's very safe from food, as kidneys eliminate the excess." Over-supplementing can cause diarrhea, nausea and lethargy, according to the expert. Magnesium supplements come in different forms for various purposes, which are absorbed in different ways. Click Here To Sign Up For Our Health Newsletter One of the most popular forms is magnesium citrate, which is typically taken orally to raise levels in the body and alleviate constipation, according to Healthline. Magnesium chloride is another good choice for correcting deficiencies, and also alleviates heartburn and constipation. For those who can't tolerate other forms, magnesium lactate and magnesium malate may be gentler on the digestive system, Healthline noted. Magnesium taurate is known to have potential benefits for regulating high blood sugar and high blood pressure, while magnesium L-threonate could potentially help support brain health. "The magnesium salts used for a calming effect are glycinate and taurate," Quattrocchi told Fox News Digital. Magnesium glycinate has also been shown to improve sleep, reduce mental health issues and treat inflammatory conditions, according to Healthline. Click Here To Get The Fox News Ap Individuals should speak with their physician before starting magnesium supplements, as it may interfere with some medications and medical article source: Do you need a magnesium supplement? Experts share symptoms of deficiency
Yahoo
4 hours ago
- Yahoo
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215), supporting the emerging link between CETP-inhibition and prevention of AD pathology -- -- NewAmsterdam to present results during the AAIC conference in July -- NAARDEN, The Netherlands and MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from prespecified Alzheimer's Disease ('AD') biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722). The pivotal Phase 3 BROADWAY study was primarily designed to evaluate the low-density lipoprotein cholesterol ('LDL-C') lowering efficacy of obicetrapib in adult patients with established atherosclerotic cardiovascular disease ('ASCVD') and/or heterozygous familial hypercholesterolemia ('HeFH'), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. As part of this pivotal registration trial for lowering LDL-C, a pre-specified sub-study was conducted to assess the effect of obicetrapib on plasma biomarkers of AD in both the full study population and in patients carrying the ApoE4 gene. 'These findings strongly support a potential preventive strategy for Alzheimer's disease,' said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. 'In this study obicetrapib, a potent CETP inhibitor, improved the progression of key plasma biomarkers of AD pathology over a 12-month period in patients with ASCVD. These data further differentiate obicetrapib and underscore the critical role CETP inhibition may have in mitigating the risk of AD progression, alongside the significant cardiovascular benefits obicetrapib has shown in our pivotal Phase 3 trials.' The AD sub-study results from BROADWAY build on genetic, Mendelian randomization, and NewAmsterdam's pre-clinical data and data from its Phase 2a clinical proof of concept trial. 'These findings have significant implications for AD prevention, especially for the over 25% of the population that carries one or two ApoE4 risk alleles and who currently lack FDA-approved prevention options,' said Philip Scheltens, professor emeritus at Amsterdam University Medical Center. 'The ability to reduce pathological biomarker progression suggests a potential to alter disease trajectory in this population, thereby delaying or preventing the onset of symptoms. The established safety profile of obicetrapib, demonstrated across multiple large clinical trials, combined with its oral administration, may greatly facilitate clinical implementation.' 'These results are the culmination of over two decades of dedicated scientific research. Approximately two thirds of patients with Alzheimer's disease carry the ApoE4 risk isoform that is associated with a much greater risk of developing AD, and the data shared today support our belief that CETP inhibition and specifically raising small functional HDL particles offers a novel and targeted approach to reducing that risk,' said John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam. 'When viewed alongside the totality of evidence generated to date, including improvements in LDL-C, small LDL particles, Lipoprotein (a), and key biomarkers associated with diabetes and renal function, these novel data on the prevention of AD-associated pathology further strengthen obicetrapib's profile as a uniquely differentiated therapy with the potential to address multiple interrelated drivers of chronic cardiometabolic disease and neurodegeneration.' The Company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference in Toronto at the end of July 2025. Design of the Pivotal Phase 3 BROADWAY Clinical Trial The 52-week, global, pivotal, Phase 3, randomized, double-blind, placebo-controlled multicenter trial evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo as an adjunct to maximally tolerated lipid-lowering therapies in patients with ASCVD and/or HeFH whose LDL-C is not adequately controlled. The trial was conducted at sites in North America, Europe, Asia and Australia. A total of 2,530 patients were randomized 2:1 to receive 10 mg obicetrapib or placebo dosed as a once-daily oral treatment, with or without food for 52 weeks. The mean baseline LDL-C for enrolled patients in the obicetrapib arm was approximately 100 mg/dL despite high intensity statin use reported by nearly 70% of patients during screening. Females comprised approximately 34% of the trial population and the median age of participants at baseline was 65 years. The primary endpoint was LS mean percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days which showed a reduction of 33% with imputation. Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo in ApoB, Lp(a), ApoA1, HDL-C, non-HDL-C, total cholesterol, and triglycerides at day 84, and on LDL-C levels at days 180 and 365. Other exploratory outcome measures included time from randomization until the first confirmed occurrence of MACE in the obicetrapib arm compared to placebo. The trial also evaluated the safety and tolerability profile of obicetrapib. Alzheimer's Sub-Study Trial In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified population of ApoE3/4 or 4/4 carriers. The sub-study included 1727 patients, including 367 ApoE4 carriers. The primary outcome measure was p-tau217 absolute and percent change over 12 months. Additional outcome measures included neurofilament light chain ('NFL'), glial fibrillary acidic protein ('GFAP'), p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215). Design of the Phase 2a Alzheimer's Trial The open-label and single-arm trial was designed to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of obicetrapib 10 mg in early AD patients carrying at least one copy of ApoE4. A total of 13 patients were given 10 mg obicetrapib and followed for 24 weeks. NewAmsterdam observed reductions in the levels of 24- and 27-hydroxycholestrol in both plasma and cerebrospinal fluid. Overall, obicetrapib was observed to be well-tolerated. No serious adverse events ('AEs') were reported, nor were any AEs considered to be related to the study drug. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Forward-Looking Statements Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's business and strategic plans, the Company's commercial opportunity, the therapeutic and curative potential of the Company's product candidate, the Company's clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and business milestones, including potential commercialization; whether topline, initial or preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use of our product candidate, if approved; the potential for varying interpretation of the AD sub-study results; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts; the effects of competition on the Company's future business; and those factors described in the Company's public filings with the Securities and Exchange Commission. Additional risks related to the Company's business include, but are not limited to: uncertainty regarding outcomes of the Company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company's business; intellectual property related claims; the Company's ability to attract and retain qualified personnel; and ability to continue to source the raw materials for the Company's product candidate. If any of these risks materialize or the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company's assessments to change. These forward-looking statements should not be relied upon as representing the Company's assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
